FDA OKs Levemir for diabetes

Shares of Denmark's Novo Nordisk have been on the rise since the FDA announced that it had approved Levemir for diabetes. Levemir will be introduced into the US market sometime over the next 12 months. "The US approval of Levemir is an important event for Novo Nordisk in the US as it completes our portfolio of insulin analogues and thereby paves the way for continued expansion of our US diabetes care franchise," said Kaare Schultz, executive vice president and COO at Novo Nordisk.

- read this article from AFX for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.